This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-09-2522v1 69/21/8516    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Kim, H. S. Articles by Kaufman, H. L. PubMed PubMed Citation Articles by Kim, H. S. Articles by Kaufman, H. L.

Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand

Department of Oncological Sciences, Mount Sinai School of Medicine, New York, New York

Requests for reprints: Howard L. Kaufman, Department of Oncological Sciences, Mount Sinai School of Medicine, 1425 Madison Avenue, Room 15-20A, New York, NY 10029. Phone: 212-241-4757; Fax: 212-241-3810; E-mail: howard.kaufman{at}mountsinai.org.

Oncolytic viral vectors have shown promise as antitumor therapeutic agents but their effectiveness is complicated by induction of antiviral antibody responses and rapid host clearance of recombinant vectors. We developed a recombinant oncolytic vaccinia virus expressing the 4-1BBL T-cell costimulatory molecule (rV-4-1BBL) and showed modest tumor regression in the poorly immunogenic B16 murine melanoma model. To improve the therapeutic potential of this vector, we tested the antitumor activity of local intratumoral injection in the setting of host lymphodepletion, which has been shown to augment vaccination and adoptive T-cell therapy. In this model, rV-4-1BBL injection in the setting of lymphodepletion promoted MHC class I expression, reduced antiviral antibody titers, promoted viral persistence, and rescued effector-memory CD8⁺ T cells, significantly improving the therapeutic effectiveness of the oncolytic vector. These data suggest that vaccination with rV-4-1BBL in the setting of host nonmyeloablative lymphodepletion represents a logical strategy for improving oncolytic vaccination in melanoma, and perhaps other cancers as well. [Cancer Res 2009;69(21):8516–25]

Key Words: 4-1BBL • Gene Therapy • Lymphodepletion • Vaccine • Vaccinia Virus